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We performed an economic analysis of an intervention to decrease ventilator-associated pneumonia (VAP) prevalence in pediatric
intensive care units (PICUs) at two Nicaraguan hospitals to determine the cost of the intervention and how eﬀective it needs to be
in order to be cost-neutral. A matched cohort study determined diﬀerences in costs and outcomes among ventilated patients. VAP
cases were matched by sex and age for children older than 28 days and by weight for infants under 28 days old to controls without
VAP. Intervention costs were determined from accounting and PICU staﬀ records. The intervention cost was approximately $7,000
for one year. If VAP prevalence decreased by 0.5%, hospitals would save $7,000 and the strategy would be cost-neutral. The ﬁnding
that the intervention required only modest eﬀectiveness to be cost-neutral and has potential to generate substantial cost savings
argues for implementation of VAP prevention strategies in low-income countries like Nicaragua on a broader scale.
1.Introduction
Ventilator-associatedpneumonia(VAP),deﬁnedaspneumo-
nia occurring more than 48h after the initiation of endotra-
cheal intubation and mechanical ventilation, is the cause of
signiﬁcant morbidity and mortality in critically ill patients
[1, 2]. While the incidence of VAP among adults is higher
than among children, pediatric VAP is associated with a 4-
fold increase in intensive care unit (ICU) length of stay, a 3-
fold increase in hospital length of stay, and higher mortality
[3].
Implementation of evidence-based quality improvement
(QI) strategies to reduce the incidence of VAP in intensive
care patient populations has become a major focus in high-
income countries, and several authors have outlined clinical
management bundles speciﬁcally for preventing VAP in
pediatric patients [4, 5]. One study conducted in the USA
reported the business case for decreasing VAP in PICU
settings [6]. However, there has been little research into such
eﬀorts in low-income country settings [7].
The incidence of VAP among pediatric patients has been
reported at between 16 and 53 cases per 1,000 ventilator-
days in Nicaraguan hospitals [8]. This is higher than the
10 per 1,000 ventilator days in Taiwan and the 3.7 per
1,000 ventilator days in the USA [9, 10]. A QI intervention
was implemented in two hospitals in Managua, Nicaragua,
by USAID’s Health Care Improvement Project (HCI) in
partnership with the Ministry of Health (MINSA). The goal
of the intervention was to decrease the risk of pneumonia
among pediatric patients on mechanical ventilation. This
study is an economic analysis of the QI intervention to
decrease VAP prevalence in PICUs in the two hospitals from
the perspective of MINSA and HCI. Speciﬁcally, we address
three questions: (1) how much does the QI intervention cost2 International Journal of Pediatrics
to implement?, (2) how eﬀective does the intervention need
to be in order to be cost-neutral?, and (3) what are the most
important variables in the model?
2. Methods
2.1. Design and Sampling. We conducted a small matched
cohort study to determine the diﬀerence between ventilated
pediatric patients who developed VAP and those who did
not in terms of lengths of stay, case fatality ratios, antibiotic
usage, and diagnostic tests conducted. Fifty patient charts
were reviewed at the two participating hospitals: 25 cases
and 25 controls were matched on sex and age within 30 days
for children older than 28 days and on weight within 1,000
grams for neonates under 28 days of age. Fifteen consecutive
cases and 15 controls were sampled from Bertha Calderon
Hospital, while ten consecutive cases and ten controls were
sampled from Manuel de Jesus Rivera Children’s Hospital.
2.2. Intervention. An initial evaluation identiﬁed care prac-
tices that did not meet evidence-based standards of care. The
intervention involved an improvement specialist working
with front-line PICU staﬀs working as “quality improvement
teams” to identify speciﬁc deﬁciencies in clinical practice,
implement changes, and evaluate their eﬀectiveness in
achieving compliance with care standards. Speciﬁc interven-
tions implemented by the teams included the correct use
of antiseptics and disinfectants, proper hand hygiene before
handling the patient or ventilator equipment, frequent oral
care for the patient, draining the ventilator circuit of con-
densate frequently, and positioning the patient with the head
of the bed elevated at least 30 degrees. Team members were
also responsible for monitoring compliance with MINSA
infection prevention standards [11] and indicators of VAP as
well as other nosocomial infections in their facilities. A coach
from HCI met monthly with the QI teams to analyze results
of the training on hygiene and infection prevention behavior
change and propose actions when suboptimal performance
was identiﬁed. A standardized treatment algorithm to reduce
aspiration of secretions was created and adopted by the
MINSA as the standard for use in ICUs. QI teams from the
two hospitals met periodically to share the results of the
changes in procedures of care they had implemented.
Planning and development of the program and coaching
personnel were funded by HCI. MINSA covered the costs of
the clinical staﬀ’s time and any additional expenses involved
with implementation of the intervention, such as additional
antiseptic supplies. The Nicaraguan MINSA gave approval
for this intervention and its evaluation.
2.3. Data Collection. Data on lengths of hospitalization,
discharge status, use of antibiotics, and diagnostic tests were
obtained from a retrospective review of the hospital charts
for the cases and controls sampled from the two hospitals.
Data on the costs of the QI intervention were collected
from a review of HCI records and approximations made
by HCI personnel of the time spent by the participating
hospital staﬀ at the coaching sessions. The costs paid by HCI
for implementation of the intervention were determined
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Figure 1: Analysis framework for comparing the QI intervention to
business-as-usual.
by examining the project’s accounting records and include
the HCI staﬀ time required to design and implement
the QI intervention, travel expenses, administration, and
other expenses. Costs to MINSA for the intervention were
calculated based on the time they devoted to the activities
of the intervention described above, even though these tasks
were completed within their normal work day and did not
incur additional expenditure.
Hospitalization costs were obtained by summing salaries
of doctors and nurses required to staﬀ the ICU, multiplying
it by the proportion of patients under care for VAP, and
calculated according to the salary rates published by MINSA.
Hospital bed costs, which included food, water, medical
supplies, electricity and other utilities, cleaners, and ancillary
staﬀ, were calculated based on the rates quoted by admin-
istrators from both hospitals and divided by the number of
patientsincaretoobtainaper-patientcostﬁgure.Thecostof
diagnostic services and antibiotics prescribed and consumed
during hospitalization was calculated based on the MINSA
price list of basic medicines, using the deﬁned daily dose
methodology described by Maxwell et al. [12]. We calculated
the costs of hospitalization based on the methodology
developed by Pan American Health Organization [13]. All
costs were calculated based on information provided by
administrators of the two hospitals and reported in 2008 US
dollars.
2.4. Analysis. We used the decision tree analysis to compare
the costs and eﬀectiveness of the two strategies: with the
QI intervention and business-as-usual (Figure 1). Three
outcome measures were used: disability-adjusted life years
(DALYs) averted, hospital days averted, and deaths averted.
For DALY calculations, a 3% per annum discount rate was
applied, and age and disability weighting was used according
tothemethodsdescribedbyMurrayandLopez[14]andused
for pediatric ICU cases in developing countries by Proﬁt et
al. [15]. We used a one-month length of illness for children
surviving VAP and a three-week length of illness for non-
VAP ventilated children. This was based on the averages
determined from the matched cohort study.
The outcome was measured as an incremental cost
eﬀectiveness ratio (ICER), the formula for which is given in
(1). A negative numerator means that the intervention costs
less.AnegativedenominatormeansthattheinterventionwasInternational Journal of Pediatrics 3
Table 1: Costs of the QI intervention and ICU inputs.
Cost items Cost
($US)
QI intervention (for 1 year) Development 922
Coaching 4860
Management 540
Hospital staﬀ time 360
Total 6682
Antibiotics per day (VAP) 4.41/day
Antibiotics per day
(non-VAP) 1.69/day
Cultures 4.88
Hospital bed (ventilated
patient)/day 343
more eﬀective. If both the numerator and denominator are
positive, the intervention saves money and improves health
and is therefore strongly recommended.
We were not able to determine the eﬀectiveness of the QI
intervention in decreasing the incidence of VAP due to the
absence of baseline data. Consequently, a range of levels of
eﬀectiveness were entered into the decision tree model to
determine how the incremental cost eﬀectiveness changed.
From these calculations, the point at which the cost savings
due to fewer cases of VAP among ventilated ICU patients
wereequaltothecostoftheQIintervention wasdetermined.
Eﬀectiveness at a level higher than this cost-neutral point
would lead to both lower costs and better health outcomes,
deﬁned as a decrease in the incidence of VAP in this
population.
Incremental cost eﬀectiveness ratio
=
cost at QI sites after intervention −cost at QI sites before intervention
Length of stay at QI sites after intervention −length of stay at QI sites before intervention
.
(1)
To determine the relative importance of the input variables,
we increased their values individually in turn by 1%,
recalculated the model and recorded the eﬀect this had on
the outcome. The higher the percent change in the outcome,
the more important the change in the input variable.
3. Results
The costs of the intervention are given in Table 1. ICU staﬀ
time for the intervention was based on a two-person team
(onedoctorandonenurse)ineachhospitaldevoting3hours
to QI intervention activities every month. Although this did
not create additional expense for the hospitals, their time on
QI activities is valuedbecause they wereunable to fulﬁlltheir
clinical duties during this period. The total cost for the year-
long intervention was $6,682. The cost of the coaching visits
to the two hospitals conducted by HCI Project personnel was
the highest expense, accounting for 73% of the total.
DatafromthematchedcontrolstudyaregiveninTable 2.
The average number of days of hospitalization was 17 days
higher among patients with VAP than those with no VAP
diagnosis (P<0.001). There was a 40% higher case fatality
ratio among patients with VAP (P = 0.02). The average
number of laboratory cultures was also higher by 2.9 or
96% among VAP patients (P = 0.01). The average cost of
hospitalization for a patient with VAP was $9,686, while the
average cost for a non-VAP ventilated patient was $3,779.
We modeled the ICERs of the QI intervention for various
levels of eﬀectiveness from a decrease of 0.3% in the preva-
lence of VAP to a decrease of about 3% for the denominators
of DALYs,hospital daysaverted,anddeaths averted (Figure 2).
For all outcome denominators, the break-even point occurs
when the eﬀect of the QI intervention is a decrease in the
prevalence of VAP by 0.5%, that is, if the eﬀect of the QI
intervention was to decrease the prevalence from 227 cases
per 1000 ventilated patients to 222 cases per 1000. There
would be increasingly large savings to the health system as
the eﬀectiveness of the intervention gets progressively higher
than the 0.5% reduction in VAP prevalence. As shown in the
three graphs in Figure 2, the ICERs appears to reach a point
of diminishing returns in terms of cost savings due to the
QI intervention at an eﬀectiveness level of around a 2.5%
decrease in the prevalence of VAP.
The length of hospitalization for VAP cases had the
greatest eﬀect of all of the input variables on the relative cost
eﬀectivenessof theintervention, witha 1% increasein length
of stay causing a 1.82% increase in the ICER. Variables that
hadlittleeﬀectonthecosteﬀectivenessresultincludethecost
of antibiotics, the number and cost of laboratory cultures,
and the cost of the QI intervention (Table 3).
4. Discussion
For an investment of less than $7,000 for the development
and implementation over 1 year, the QI intervention would
be cost-neutral if it decreased the prevalence of VAP by
0.5%, that is, resulted in 5 fewer cases of VAP per 1,000
mechanically ventilated patients in ICU. If the intervention
decreased the prevalence more than 0.5%, there would be
signiﬁcant cost savings as well as improved health outcomes.
The prevalence of VAP in our study population was
22.7%, which is comparable to the prevalence of 20% found
in the Punjab [17]. The average length of stay for a VAP
patient of 27.9 was similar to the 22 to 37 (depending on the
management protocol) found in Taiwan [9]. Taira et al. [18]
found lengths of stay for VAP and non-VAP ICU patients of
28.7 and 12, respectively, which was very close to the lengths
ofstayseeninthisstudy.Themagnitudeofthecostdiﬀerence
for hospital care between VAP and non-VAP of $5,907 was
slightly higher than diﬀerence of $4,890 found in Argentina4 International Journal of Pediatrics
Table 2: Noncost inputs for cost eﬀectiveness analysis model.
Inputs Estimate Source
Prevalence of VAP among ventilated patients 0.227 Matched cohort study
Case fatality ratio (CFR) for VAP cases 0.5 Matched cohort study
CFR for controls 0.1 Matched cohort study
Average length of stay (LOS): VAP case in days 27.9 Matched cohort study
Average LOS: controls in days 10.9 Matched cohort study
Average number of cultures: VAP cases 5.96 Matched cohort study
Average number of cultures: controls 3.04 Matched cohort study
DALYs severe pneumonia (VAP) 0.056 Hsieh et al. [9]
DALYs severe non-VAP illness 0.037 Hsieh et al. [9]
DALYs death 30.5 Hsieh et al. [9]
Life expectancy Nicaragua in years 73 PAHO [16]
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Figure 2: ICER of the QI intervention at diﬀerent levels of eﬀectiveness.
from data collected in 2001 [19]. It was less than the $30,000
diﬀerence found in a Unites States (USA) hospital. However,
considering the substantially lower expenditures on health
and the lower cost of labor in Nicaragua compared with the
USA, our results represent a greater practical diﬀerence [20].
The average length of stay for VAP cases was the variable
in the model that had the greatest impact on the overall
result. The average length of stay for non-VAP cases and the
case fatality ratios of both VAP and non-VAP cases also had
a signiﬁcant impact on the result. This is consistent with
the ﬁnding of a large diﬀerence in case fatalities and lengths
of stay between the cases and controls found in the study.
The ﬁnding that the cost of the QI intervention itself had
only a small impact on the overall cost eﬀectiveness suggests
that even if the QI intervention costs substantially more to
implement, its eﬃciency would decrease by only a small
degree.
The ﬁnding of only a small improvement needed to
achieve cost savings is consistent with the ﬁndings of Sharma
et al. [17] who reported that increased compliance with
evidence-based prophylactic measures led to a decrease in
VAP cases with an associated signiﬁcant cost savings among
adult ICU patients.
Prior to the QI intervention, the participating ICUs did
not record the occurrence of VAP among all mechanically
ventilated patients in the unit. The incidence of VAP was notInternational Journal of Pediatrics 5
Table 3: Eﬀects of a 1% increase in input variables on incremental cost eﬀectiveness ratio.
Variable % Variation Direction
(cost eﬀectiveness of QI intervention)
LOS (VAP) 1.82 Increase
CFR for VAP 1.33 Increase
Cost of hospital bed 1.13 Increase
Length of stay (non-VAP) 0.60 Decrease
CFR (non-VAP) 0.22 Decrease
Incidence of VAP postcollaborative 0.22 Decrease
Cost of antibiotics 0.10 Increase
Number of cultures (VAP) 0.08 Increase
Cost of cultures 0.08 Increase
Number of cultures (non-VAP) 0.07 Decrease
Cost of QI intervention 0.07 Decrease
distinguished from infections from other causes, and it was
impossible to distinguish VAP cases from other ICU-ac-
quired infections ex post facto in this case due to limitations
in patient clinical records. Therefore, baseline data, from
whichtheeﬀectivenessoftheinterventioncouldbemeasured
by comparing to data collected at the end of the QI interven-
tion, were not available. Because changes in infection control
practice were made rapidly at the onset of the intervention, it
was considered invalid to use the data of occurrence on VAP
collectedconcurrentlyatthebeginningoftheintervention.If
MINSA decides to expand the QI intervention to other ICU
facilitiesinNicaragua,werecommendthatmoreattentionbe
paid to collection of valid baseline data so that changes in the
occurrence of VAP associated with implementation of the QI
intervention can be quantiﬁed.
Other researchers have quantiﬁed the changes in occur-
rence of nosocomial infections associated with improved
compliance with hand hygiene standards. Taira et al. [18]
found a decrease in nosocomial infections in a hospital-
wide intervention in Switzerland from 16.9 to 9.9% over the
course of a year. Acosta-Gnass et al. [19]f o u n dar e d u c t i o n
in the incidence of VAP from 28 cases per 1,000 ventilator
days to 13.2 cases in the USA If the impact in reduction of
VAP incidence in the participating hospitals in Nicaragua
was anything close to the impact shown in these other
studies, the cost eﬀectiveness of the QI intervention would
be substantial. Given that the reduction in prevalence of VAP
needed for the cost savings to be equal to the cost of the
QI intervention is only 0.5%, we consider it highly probable
that this intervention was associated with signiﬁcant positive
outcomes for the participating hospitals.
5. Limitations
This analysis took the narrow perspective of the funders
(USAID and MINSA) and did not include costs to the pa-
tient’s family or caregivers as would have been the case if the
societal perspective had been taken. The costs to caregivers
wouldbeloweriftheincidenceofVAPdecreasedasexpected,
making the QI intervention even more cost-eﬀective than
these results.
We were unable to control for confounding factors such
as the patients’ preexisting health status in the matched
cohort study. It is plausible that patients who develop cases
of VAP are in poorer health before infection than those who
do not develop VAP, and may therefore have worse outcomes
regardless of VAP infection. Accounting for this factor would
possibly decrease the measure of cost eﬀectiveness seen here.
A study with a much larger sample size is required to control
for such confounders. Matching patients by pediatric risk
of mortality (PRISM) scores or pediatric index of mortality
(PIM) scores would also have helped account for diﬀerences
in preexisting severity of illness. However, the use of these
scores is not routine in Nicaraguan PICUs and their validity
and reliability have been challenged in some studies [20, 21].
The diﬀerences between VAP and non-VAP mechanically
ventilated PICU patients in this study were consistent with
thoseofalargerstudyinwhichseverityscorediﬀerenceswere
accounted for [3].
This study was conducted in the two largest pediatric
hospitals in Nicaragua. They have greater resources, higher
patient numbers, and larger staﬀ than other hospitals in the
country. It is possible that implementation of the inter-
vention at these other hospitals may involve diﬀerent per-
patient costs and result in diﬀerent levels of eﬀectiveness.
Ideally, sampling across other hospitals in Nicaragua would
have supported the case for generalizability of the ﬁndings.
However, given the simple nature of the intervention, we
assume that it could be implemented with similar costs and
eﬀectiveness.
The QI interventions studied here was a time-bound
strategy designed to implement changes to bring about
improvements in the processes of care to ultimately achieve
better health outcomes and then to make these improve-
ments sustainable beyond the life of the intervention.
If improvements are institutionalized and the QI teams
disband or move on to address other gaps in quality perfor-
mance, the intervention’s cost eﬀectiveness will increase in
subsequent periods compared to the result shown here.6 International Journal of Pediatrics
This is the ﬁrst economic evaluation of which we are
aware that examines the costs and eﬃciency of a QI
intervention for nosocomial infection prevention in tertiary
care in a low-income country. The incidence of VAP in
developing country ICUs is reported to be four times
higher than ICUs in the USA [10]. The need for eﬀective
interventions to decrease the occurrence of VAP in ICUs is
clear, and determining their cost and eﬃciency is crucial
for informing health policy decision-makers on the aﬀord-
ability and sustainability of the strategies in comparison to
competing needs for health resources. This study indicates
that modest inputs for the QI intervention are likely to
produce signiﬁcant cost savings even with only a modest
decreaseintheprevalenceofVAP.We,therefore,recommend
implementation of this QI intervention in all pediatric ICUs
i nN i c a r a g u a .H o w e v e r ,m o r ed a t ao ne ﬀectiveness of the
intervention in decreasing the occurrence of VAP should be
added to the analysis when it becomes available.
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